Development Stage: Clinical stage
Indication: Recurrent aphthous stomatitis, hand-foot-mouth disease (HFMD)-induced oral ulcers, and radiotherapy/chemotherapy-induced oral mucositis
Key Asset Highlights:
（1）Possesses dual pharmacological mechanisms of anti-inflammation and anti-infection, capable of potent inhibition of multiple key pro-inflammatory factors that drive mucosal injury and ulcer progression.
（2）Effectively alleviates local mucosal inflammatory responses, accelerates oral mucosal tissue repair and ulcer healing, and relieves pain symptoms associated with various oral ulcer conditions.
（3）Covers a broad spectrum of oral ulcer indications, including recurrent idiopathic aphthous ulcers, pediatric HFMD-related oral lesions, and refractory mucosal damage caused by tumor chemoradiotherapy.
（4）Demonstrates excellent clinical efficacy and safety profiles in early-stage clinical studies, with superior local therapeutic effects and low systemic exposure compared with conventional symptomatic treatments.
（5）Features favorable local tissue affinity and stable pharmacological performance, supporting safe and repeated administration for recurrent and therapy-induced oral mucosal diseases.
（6）Backed by a comprehensive intellectual property portfolio, securing exclusive and stable clinical development and commercialization rights across the Greater China region and global markets.
If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.
Email: BD@drugtimes.cn
Thank you very much!
【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
